Brokerages expect Clovis Oncology (NASDAQ:CLVS) to announce earnings per share of ($1.01) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Clovis Oncology’s earnings, with the highest EPS estimate coming in at ($0.88) and the lowest estimate coming in at ($1.11). Clovis Oncology reported earnings of ($1.89) per share in the same quarter last year, which would suggest a positive year over year growth rate of 46.6%. The company is scheduled to issue its next earnings report on Thursday, November 5th.
On average, analysts expect that Clovis Oncology will report full-year earnings of ($4.38) per share for the current fiscal year, with EPS estimates ranging from ($4.69) to ($4.18). For the next fiscal year, analysts anticipate that the business will post earnings of ($2.54) per share, with EPS estimates ranging from ($3.36) to ($1.59). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Clovis Oncology.
Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.04) by ($0.11). The company had revenue of $39.89 million for the quarter, compared to analyst estimates of $44.65 million.
CLVS has been the topic of several recent analyst reports. BidaskClub upgraded shares of Clovis Oncology from a “sell” rating to a “hold” rating in a report on Saturday, September 19th. HC Wainwright restated a “buy” rating and set a $23.00 target price on shares of Clovis Oncology in a report on Monday, September 21st. Finally, ValuEngine cut shares of Clovis Oncology from a “buy” rating to a “hold” rating in a report on Wednesday, September 16th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $9.64.
NASDAQ:CLVS traded down $0.17 during trading hours on Monday, hitting $5.75. The company had a trading volume of 2,592,060 shares, compared to its average volume of 5,249,263. The company has a market capitalization of $507.15 million, a PE ratio of -0.95 and a beta of 2.26. The stock has a 50-day moving average price of $5.74 and a 200 day moving average price of $6.58. Clovis Oncology has a 52 week low of $2.93 and a 52 week high of $17.37.
Institutional investors have recently made changes to their positions in the stock. Great West Life Assurance Co. Can bought a new position in Clovis Oncology in the 2nd quarter worth about $32,000. Private Advisor Group LLC bought a new position in Clovis Oncology in the 2nd quarter worth about $35,000. Canada Pension Plan Investment Board bought a new position in Clovis Oncology in the 2nd quarter worth about $41,000. Ameritas Investment Partners Inc. boosted its stake in Clovis Oncology by 61.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,387 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 2,420 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. bought a new position in Clovis Oncology in the 1st quarter worth about $72,000. Institutional investors own 52.80% of the company’s stock.
About Clovis Oncology
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.